AZN catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
- Completion LockedPhase 1/Phase 2NCT04068610COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRCMedImmune LLC · Metastatic Microsatellite-stable Colorectal CancerActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Oct 10, 2022Actual
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT06267729Study of AZD0754 in Participants With Metastatic Prostate CancerAstraZeneca · Metastatic Prostate CancerRecruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Nov 24, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT02546661Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder CancerAstraZeneca · Muscle Invasive Bladder CancerActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Mar 18, 2020Actual
- Interventions
- Locked
- Completion LockedPhase 1NCT07290283A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD3974 in Healthy ParticipantsAstraZeneca · Healthy ParticipantsRecruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Dec 8, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT07128615A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)AstraZeneca · Influenza AActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Jan 28, 2026Actual
- Interventions
- Locked
- Completion LockedPhase 1NCT02264678Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer AgentsAstraZeneca · Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian CancerActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Mar 4, 2025Actual
- Interventions
- Locked
- Completion LockedPhase 1NCT00750841Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid TumoursAstraZeneca · Solid TumorsActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Jul 30, 2009Actual
- Interventions
- Locked
- Completion LockedPhase 1NCT02143466AZD9291 in Combination With Ascending Doses of Novel TherapeuticsAstraZeneca · Advanced Non Small Cell Lung CancerActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Mar 4, 2020Actual
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT03837899Durvalumab and Tremelimumab for Pediatric MalignanciesAstraZeneca · Pediatric CancerActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Feb 28, 2023Actual
- Interventions
- Locked
- Completion LockedPhase 1NCT06147037A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid TumoursAstraZeneca · Advanced Solid TumorActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Dec 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07534592A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy ParticipantsAstraZeneca · Healthy ParticipantsActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Jan 25, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT06151964A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With...AstraZeneca · Overweight and ObesityActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Jan 29, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07000149A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCCAstraZeneca · Advanced Clear Cell Renal Cell CarcinomaActive, not recruitingAZNLeadRCUSCollaborator
- Enrollment
- Locked
- Primary completion
- Jan 29, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07024823A Study to Investigate Safety, Tolerability, PK, and PD of AZD4248 in Healthy Participants, Participants With CKD and Type 2 Diabetes...AstraZeneca · Chronic Kidney DiseaseRecruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Jan 29, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07546760A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234AstraZeneca · Hepatic ImpairmentRecruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Feb 4, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT06713369AZD5305 hADME in Patients With Advanced Solid MalignanciesAstraZeneca · Locally Advanced or Metastatic Solid TumorRecruitingAZNLeadFTRECollaborator
- Enrollment
- Locked
- Primary completion
- Dec 31, 2026Sponsor estimate
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 16 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.